GlassScriptPhysician profile
Alka Sawhney
NPI 1124076955
$8,746.56
in general payments reported to CMS, 2019-2025
47 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,686 · 2020: $747 · 2021: $43.70 · 2022: $1,425 · 2023: $1,760 · 2024: $595 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,035 · Food and Beverage: $785 · Education: $25.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,035.00 |
| Food and Beverage | $784.52 |
| Education | $25.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $3,044.40 | 2022-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $952.79 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Incyte Corporation | $925.40 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $460.28 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $277.15 | 2019-2025 | Reblozyl |
| Genzyme Corporation | $235.25 | 2019-2025 | |
| Seagen INC. | $211.55 | 2019-2020 | |
| Genentech USA, INC. | $208.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $193.10 | 2019-2020 | |
| Daiichi Sankyo INC. | $185.13 | 2019-2025 | Datroway, Enhertu |
| Astellas Pharma US INC | $180.71 | 2019-2025 | Vyloy |
| Merck Sharp & Dohme LLC | $153.13 | 2019-2025 | |
| Amgen INC. | $150.60 | 2019 | |
| Pfizer INC. | $146.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.31 | 2019-2025 | Iclusig |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Sawhney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.